Trial Profile

Bortezomib Sensitization of Recurrent Grade-4 Glioma With Unmethylated MGMT Promoter to Temozolomide Phase 1B/II Study

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bortezomib (Primary) ; Temozolomide (Primary)
Indications Glioblastoma; Glioma
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms BORTEM-17

Most Recent Events

04 Aug 2026 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
04 Aug 2026 Planned primary completion date changed from 30 Jun 2025 to 30 Dec 2026.
27 Feb 2024 Planned End Date changed from 30 Aug 2023 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com